Zepto, a precision pulse device that creates an accurate and reproducible capsulotomy that is quick, safe, and affordable.
Orasis is an emerging ophthalmic pharmaceutical company with the goal of making near vision clear again. We are committed the Ophthalmology and Optometry segments because we know that presbyopia is ubiquitous. By virtue of our first in class formulation, Orasis is well positioned to be first line therapy in this emerging category by addressing a significant unmet need for patients.
Re-Vana Therapeutics is developing sustained release ophthalmic therapeutics that can reduce the frequency of intravitreal injections required to treat a wide range of retinal diseases, including neovascular age-related macular degeneration. The Re-Vana platform has the potential to deliver at least 4 to 6 months sustained delivery of a large molecule biologic, including anti-VEGF therapies. Re-Vana’s technology could spur a new generation of glaucoma medications that may reduce or eliminate the need for eye drops by delivering small molecules for 6 to 9 months or longer.
Transforming the lens industry by being able to optimize a lens after implantation. RxSight has developed breakthrough intraocular lens technology for use in cataract and lens replacement surgery. Designed by a Nobel Prize winning scientist, RxSights’s Light Adjustable Lens (RxLAL) utilizes light to enable physicians to make office-based refractive adjustments after it has been implanted in the eye.
Sydnexis is a San Diego based clinical stage pharmaceutical company currently in the middle of a pivotal Phase 3 study, focused on the development of a novel proprietary formulation of low dose atropine for the treatment of myopia. Myopia is a growing public health challenge worldwide that’s expected to affect 5 billion people by the year 2050.
Tarsus is a late clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class therapeutic candidates to address large market opportunities initially in ophthalmic conditions where there are limited treatment alternatives, starting with Demodex blepharitis. Tarsus is developing a pipeline of products, with the lead candidate, TP-03, in clinical development to treat Demodex blepharitis. TP-03 is a novel, topical ophthalmic drug that specifically targets the Demodex mite’s nervous system, thereby treating the underlying cause of disease.
TearClear is an emerging global ophthalmic pharmaceutical company focused on disrupting the way current topical medications are delivered to the ocular surface. The company’s first in class pharmaceutical platform ensures patient safety and compliance by capturing preservatives prior to administration on to the ocular surface. TearClear’s lead candidates in glaucoma will pave the way for future indications across multiple programs in development.